ISOThrive Inc. is a clinical-stage biopharmaceutical company that is developing novel, microbiome-targeted therapeutics for gastrointestinal diseases. Its lead product, ISOT-101, is a first-in-class treatment being evaluated for Non-Erosive Reflux Disease (NERD). The company focuses on addressing significant unmet medical needs in this area.

pharma.isothrive.com

Biopharma

Therapeutics

Pharmaceutical

Iso Thrive Inc. announced it raised $5.2 Million in an initial filing from an offering of $6 Million

Company Information

Related People

Iso Thrive Inc. announced it raised $5.2 Million in an initial filing from an offering of $6 Million

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information